Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
US biotech Anixa Biosciences has established a strategic alliance and license agreement with Cleveland Clinic for an innovative breast cancer vaccine technology. No financial terms of the deal were disclosed. 18 July 2019
Biotechnology
Privately-held US biotech Skyhawk Therapeutics has announced a multi-target exclusive option and license agreement with the Roche company Genentech to develop and commercialize small molecules that modulate RNA splicing. 17 July 2019
Biotechnology
US biopharma Anavex Life Sciences has presented new clinical data identifying gut microbiota biomarkers associated with improved response in Alzheimer’s disease patients treated with its selective sigma-1 receptor agonist. 17 July 2019
Biotechnology
Antibiotic and immuno-oncology specialist Polyphor has finally closed the Phase III PRISM MDR and UDR studies of murapavadin, the Swiss firm’s lead candidate for hospital-acquired and ventilator-associated bacterial pneumonia. 17 July 2019
Biotechnology
Gilead Sciences announced today that John McHutchison, chief scientific officer and head of R&D, has decided to leave the company, effective next month. 17 July 2019
Biotechnology
Nordic biotech firm Swedish Orphan Biovitrum today announced financial results for the second quarter of 2019, posting revenues of 3,163 million Swedish kronor ($337.2 million), a rise of 38% (+32% at constant exchange rates) compared with the like 2018 period. 17 July 2019
Biotechnology
UK biopharma company PureTech Health today announced it has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. 17 July 2019
Biotechnology
Shares of USA-based ImmunoCellular Therapeutics closed up 6.7% at $0.018 yesterday, after the biotech firm announced an agreement with an unnamed privately held biotechnology company for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. 17 July 2019
Biotechnology
There was positive news for Swiss pharma giant Novartis, with the UK medicines cost-effectiveness watchdog reversing an earlier negative decision and agreeing wider National Health Service use for its cancer drug Kisqali (ribociclib). 17 July 2019
Biotechnology
A new R&D deal will see nerve specialist Convelo Therapeutics collaborate with Roche subsidiary Genentech. 16 July 2019
Biotechnology
The first induced pluripotent stem (iPS) cell-derived CAR-T therapy developed in a collaboration involving the Japanese pharma major Takeda has entered process development toward clinical testing. 16 July 2019
Biotechnology
Zymeworks today announced that its global biopharma partner Celgene has selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the companies’ 2014 Azymetric collaboration and licensing agreement. 16 July 2019
Biotechnology
Japan’s Sosei Group Corp has entered into a multi-target research collaboration and license agreement with Genentech, the US biotech subsidiary of Swiss pharma giant Roche, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (GPCR) targets of interest to Genentech. 16 July 2019
Biotechnology
Replacement factors are the current standard-of-care for both hemophilia A and B, representing 97% of the total sales of the hemophilia market in 2018. 16 July 2019
Biotechnology
Novartis today announced the US Food and Drug Administration accepted the Swiss pharma giant’s Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine crizanlizumab (SEG101). 16 July 2019
Biotechnology
Dutch kidney specialist AM-Pharma has raised 116 million euros ($133 million) from a European syndicate of new and existing investors. 16 July 2019
Biotechnology
Encouraging Phase II data doubled Capricor Therapeutics’ share price on Monday, amid modest volumes of trade in New York. 16 July 2019
Biotechnology
GlaxoSmithKline has announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season. 16 July 2019
Biotechnology
Seqirus, a global leader in influenza prevention and part of Australia’s CSL Limited, announced today it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the USA for the 2019/20 influenza season. 15 July 2019
Biotechnology
German privately-held drugmaker Boehringer Ingelheim has bought Swiss biotech firm AMAL Therapeutics for up to 326 million euros ($366 million). 15 July 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze